Company claims products empower physicians with accurate information, leading to improved patient outcomes.

Based on its recent analysis of the global AI-based stroke imaging and diagnosis market, Frost & Sullivan recognizes RapidAI with the 2020 Global Company of the Year Award. Its clinically-validated Rapid platform leverages AI to support almost all phases of stroke imaging workflow, from initial interpretation to final reporting. The company says RapidAI products help perform the early identification of stroke and aneurysm using software such as Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid LVO, Rapid CTP, Rapid MRI and SurgicalPreview, to expedite treatment.

“RapidAI has a footprint across 1,600 hospitals in more than 60 countries. In addition to a global distribution network, the company leverages partnerships with various healthcare technology leaders such as Siemens Heathineers, Samsung Neurologica, Mobile Heartbeat, and Halo Health to grow its customer base and improve brand loyalty,” said Parth Shah, Senior Research Analyst. “The company’s products make hospitals more responsive while enabling better transfer decisions for patients. As a result, RapidAI not only saves time and costs but improves long-term outcomes by enabling faster stroke interventions.”

According to the company, RapidAI can be integrated with almost every CT and MRI manufacturer model and make. Its workflow implementation requires minimal effort, while its software platform is fully automated and works on a single virtual or physical server within the hospital firewall. The RapidAI team configures the server using remote access via a Site2Site VPN tunnel, client-based VPN connection, or portal-based connection. RapidAI’s installation and implementation teams also work with the client’s IT team to schedule and optimize upgrades.

“The company’s Rapid Web App extends access into yet another user environment, offering stroke team members a convenient way to view real-time browser notifications regarding new cases and enable workflow communications via a desktop or laptop. The Rapid Mobile App is another useful tool that provides anytime-anywhere alerts and access to RapidAI results,” noted Shah. “Overall, the company’s relentless focus on innovation and strategic technological acquisitions enables the development of new capabilities that will drive continuing growth and improve vascular care globally.”

Each year, Frost & Sullivan presents a Company of the Year award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration: www.frost.com

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact us: Start the discussion.

About RapidAI

RapidAI is the worldwide leader in advanced imaging for stroke. Based on intelligence gained from over 1,000,000 scans, from more than 1,600 hospitals in over 60 countries, the Rapid® platform uses artificial intelligence to create high quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans. The Rapid imaging platform includes Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid LVO, Rapid CTP, and Rapid MRI. RapidAI also offers SurgicalPreview®, a comprehensive aneurysm management platform.

RapidAI empowers clinicians to make faster, more accurate diagnostic and treatment decisions for stroke and aneurysm patients using clinically-proven, data-driven technology. With our validated, trusted products developed by medical experts, clinicians worldwide are improving patient care and outcomes every day. For more information, visit RapidAI.com.